Overview

This trial is active, not recruiting.

Condition glioma
Treatments ly2157299, radiation, temozolomide
Phase phase 1/phase 2
Target TGFBR1
Sponsor Eli Lilly and Company
Start date April 2011
End date August 2015
Trial size 62 participants
Trial identifier NCT01220271, 11585, H9H-MC-JBAI

Summary

The purpose of this trial is to show proof of concept that by blocking the Transforming Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical benefit.

Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with radiochemotherapy with temozolomide for Phase 2 in patients with glioma eligible to receive radiochemotherapy with temozolomide (e.g. newly diagnosed malignant glioma World Health Organization Grade III and IV).

Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in combination with standard radiochemotherapy in patients with newly diagnosed glioblastoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
During Radiation therapy: Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks. LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Temozolomide: 75 mg/m2 taken daily for 6 weeks. After Radiation Therapy: LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles. Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
ly2157299
Administered orally
radiation
Administered as approved
temozolomide
Administered orally
(Experimental)
During Radiation therapy: Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks. LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Temozolomide: 75 mg/m2 taken daily for 6 weeks. After Radiation Therapy: LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles. Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
ly2157299
Administered orally
radiation
Administered as approved
temozolomide
Administered orally
(Experimental)
During Radiation therapy: Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks. LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Temozolomide: 75 mg/m2 taken daily for 6 weeks. After Radiation Therapy: LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles. Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
ly2157299
Administered orally
radiation
Administered as approved
temozolomide
Administered orally
(Experimental)
During Radiation therapy: Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks. Temozolomide: 75 mg/m2 taken daily for 6 weeks. After Radiation Therapy: Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
radiation
Administered as approved
temozolomide
Administered orally

Primary Outcomes

Measure
Phase 1: Recommended dose for Phase 2 portion
time frame: Baseline to phase 1 completion
Phase 2: Relationship of change in response biomarker to clinical benefit
time frame: Baseline through discontinuation from any cause

Secondary Outcomes

Measure
Phase 1: Pharmacokinetics - Concentration Maximum
time frame: Baseline, prior to first dose of cycle 1 and 2 and on days 1, 3, 8, 14, 15 and 16
Phase 1: Number of patients with a tumor response
time frame: Baseline to Progressive Disease
Phase 2: Overall Survival at 12 Months
time frame: Randomization to date of death from any cause at 12 months
Phase 2: Overall Survival
time frame: Randomization to date of death from any cause
Phase 2: Progression Free Survival
time frame: Randomization to measured progressive disease or death from any cause
Phase 2: Proportion of patients achieving an objective response (Response Rate)
time frame: Randomization to measured progressive disease
Phase 2: Duration of tumor Response
time frame: Time of response to measured progressive disease or death from any cause
Phase 2: Time to Treatment Failure
time frame: Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause
Phase 1: Pharmacokinetics - Time to Concentration Maximum
time frame: Baseline, prior to first dose of cycle 1 and 2 and on days 1, 3, 8, 14, 15 and 16
Phase 1: Pharmacokinetics - Area under the Curve
time frame: Days 12 to 14 in cycle 1 and in cycle 3
Phase 2: Change from baseline in MD Anderson Symptom Inventory - Brain Tumor
time frame: Baseline, 30 day post study day follow-up

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with histologically proven, newly diagnosed and untreated intracranial glioblastoma including lower grade glioma which evolved into glioblastoma and who have not received any radiochemotherapy or who have World Health Organization Grade III malignant glioma (e.g., Anaplastic Astrocytomas, Anaplastic Oligoastrocytomas, Anaplastic Oligodendroglioma) (Phase 1b only) will be eligible for this protocol - Biopsy or resection must have been performed no more than 6 weeks prior to treatment - An Magnetic Resonance Imaging must be obtained within 72 hours after surgery, preferably within 48 hours - Patient must not have had prior cranial radiation therapy - Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors Patients who received Gliadel wafers at the time of original resection will be excluded - Patients must plan to begin partial brain radiotherapy within 2-6 weeks after surgery. Regular fractionated radiotherapy with photons (in any planning mode and possibly image-guided or stereotactic if deemed necessary) is performed according to the discretion of the investigator - Patients must be willing to forego other cytotoxic and noncytotoxic drug therapy against the tumor while being treated with LY2157299 and temozolomide - All patients must sign an informed consent indicating that they are aware of the investigational nature of this study - Patients must have performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale - Patients must have adequate hematologic, hepatic and renal function - Male and female patients with reproductive potential must use an approved contraceptive method,during and for 6 months after discontinuation of study treatment Women of childbearing potential must have a negative human chorionic gonadotropin pregnancy test documented within 14 days prior to treatment Exclusion Criteria: - Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study - Have moderate or severe cardiac disease as defined by any of the following: - Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension - Have documented major electrocardiogram (ECG) abnormalities that are symptomatic and are not medically controlled - Have major abnormalities documented by echocardiography with Doppler - Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress - Are unable to swallow tablets or capsules - Are pregnant or breastfeeding - Have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy - Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and stopped all therapy for that disease for a minimum of 3 years are ineligible - Have active infection that would interfere with the study objectives or influence the study compliance - Stereotactic radiosurgery, such as Gamma-Knife treatment, and brachytherapy are not allowed in this study

Additional Information

Official title Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Eli Lilly and Company.